{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6
  ],
  "modelUsed": "claude-opus-4-5",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Isatuximab + Atezolizumab",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Participants receive isatuximab (Days 1, 8, 15 in Cycle 1, then Day 1 of subsequent cycles) in combination with atezolizumab (Day 1 of each 21-day cycle) administered intravenously"
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Cohort HCC",
        "instanceType": "StudyCohort",
        "characteristic": "Participants with hepatocellular carcinoma"
      },
      {
        "id": "cohort_2",
        "name": "Cohort SCCHN",
        "instanceType": "StudyCohort",
        "characteristic": "Participants with squamous cell carcinoma of the head and neck"
      },
      {
        "id": "cohort_3",
        "name": "Cohort EOC",
        "instanceType": "StudyCohort",
        "characteristic": "Participants with epithelial ovarian cancer"
      },
      {
        "id": "cohort_4",
        "name": "Cohort GBM",
        "instanceType": "StudyCohort",
        "characteristic": "Participants with glioblastoma multiforme"
      },
      {
        "id": "cohort_5",
        "name": "Cohort E",
        "instanceType": "StudyCohort",
        "characteristic": "Participants with modified treatment schedule (evaluation not applicable for certain assessments)"
      }
    ],
    "summary": {
      "armCount": 1,
      "cellCount": 5,
      "cohortCount": 5
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Non-Randomized",
        "codeSystem": "USDM",
        "decode": "Non-Randomized"
      },
      "armIds": [
        "arm_1"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2",
        "cohort_3",
        "cohort_4",
        "cohort_5"
      ],
      "therapeuticAreas": [
        "Oncology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Non-Randomized",
        "allocationRatio": null,
        "stratificationFactors": []
      },
      "controlType": null,
      "therapeuticAreas": [
        "Oncology"
      ]
    },
    "arms": [
      {
        "name": "Isatuximab + Atezolizumab",
        "type": "Experimental Arm",
        "description": "Participants receive isatuximab (Days 1, 8, 15 in Cycle 1, then Day 1 of subsequent cycles) in combination with atezolizumab (Day 1 of each 21-day cycle) administered intravenously"
      }
    ],
    "cohorts": [
      {
        "name": "Cohort HCC",
        "characteristic": "Participants with hepatocellular carcinoma"
      },
      {
        "name": "Cohort SCCHN",
        "characteristic": "Participants with squamous cell carcinoma of the head and neck"
      },
      {
        "name": "Cohort EOC",
        "characteristic": "Participants with epithelial ovarian cancer"
      },
      {
        "name": "Cohort GBM",
        "characteristic": "Participants with glioblastoma multiforme"
      },
      {
        "name": "Cohort E",
        "characteristic": "Participants with modified treatment schedule (evaluation not applicable for certain assessments)"
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Up to 28 days before Day 1"
      },
      {
        "name": "Treatment Phase",
        "description": "21-day cycles with isatuximab and atezolizumab administration"
      },
      {
        "name": "End of Treatment",
        "description": "Assessment at treatment discontinuation"
      },
      {
        "name": "Safety Follow-up Period",
        "description": "30, 60, and 90 days after last IMP administration"
      },
      {
        "name": "Survival Follow-up",
        "description": "Every 90 days after last safety follow-up"
      }
    ]
  }
}